Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sangamo Biosciences (SGMO), Flexion Therapeutics (FLXN) and BioVie (BIVI).
Sangamo Biosciences (SGMO)
In a report released today, Liana Moussatos from Wedbush reiterated a Hold rating on Sangamo Biosciences, with a price target of $11.00. The company’s shares closed last Tuesday at $12.07.
According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 12.2% and a 48.2% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Eiger Biopharmaceuticals, and Lexicon Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sangamo Biosciences with a $20.00 average price target.
See today’s analyst top recommended stocks >>
Flexion Therapeutics (FLXN)
In a report released today, Carl Byrnes from Northland Securities maintained a Buy rating on Flexion Therapeutics, with a price target of $35.00. The company’s shares closed last Tuesday at $8.60, close to its 52-week low of $7.80.
According to TipRanks.com, Byrnes is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -7.2% and a 36.2% success rate. Byrnes covers the Healthcare sector, focusing on stocks such as Oncternal Therapeutics, Aridis Pharmaceuticals, and Adamas Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Flexion Therapeutics with a $20.11 average price target, implying a 130.6% upside from current levels. In a report issued on April 14, H.C. Wainwright also reiterated a Buy rating on the stock with a $25.00 price target.
BioVie (BIVI)
In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on BioVie, with a price target of $47.00. The company’s shares closed last Tuesday at $21.50.
According to TipRanks.com, Mamtani is a 5-star analyst with an average return of 29.6% and a 54.9% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Spectrum Pharmaceuticals, and Madrigal Pharmaceuticals.
Currently, the analyst consensus on BioVie is a Moderate Buy with an average price target of $47.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
